Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment

NCT05329792 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT05329792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Unknown status
Start date
March 9, 2023
Completion date
December 31, 2024
Enrollment
70 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bcc - basal cell carcinoma, kaposi sarcoma, keratoacanthoma of skin, malignant adnexal tumors of the skin (mats), merkel cell carcinoma, scc - squamous cell carcinoma, tumors from cutaneous t-cell lymphoma (ctcl)